SlideShare a Scribd company logo
1 of 21
Download to read offline
“For over 24 years, we’ve worked hand in hand with industry,
academic, and government researchers to help solve difficult
assay development and protein quantification problems.”
Stephen Parent, PhD
Director of Business Development
sparent@pblbio.com
(732) 777-9123 x117
PBL Assay Science History
• Founded in 1990 by Dr. Sidney Pestka
• 35 employees based in Piscataway, NJ
• World’s largest producer of interferons and related
cytokine products for the research market
– ELISA and multiplex assay kits
– Recombinant proteins
– Antibodies
– Assay services
– Custom services
High Quality Assay Solutions Interrogating
Interferon and Cytokine Biology
Assay Solutions Interrogating IFN and Cytokine Biology
• Off the Shelf Assays
– More than 70 Interferon ELISAs, antibodies and cell-
based assays
• Assay Services Offerings
– Sample Testing and Screening
– More than 40 Singulex Erenna biomarker assays
– Assay Design and Development
– Custom Services
– We provide ~ 70 different services
Assay Services Capabilities
Cell-Based Assay Development
Antiviral Assays
Cytokine/Chemokine Bioactivity Assays
Immunoassays
Development
Single Analyte & Multiplex ELISAs
Ultrasensitive Cytokine Detection Assays
using Singulex Erenna® technology
More than 40 Assays Available
Human and Mouse
Reagent Development & Characterization
Assay Optimization
Technology Transfer
Consulting in Assay Development and
Therapeutics Development
IL-17
Ultrasensitive Cytokine Detection Service
using Singulex Erenna® Immunoassay System
Modified IA process
using magnetic beads
Single Molecule
Detection (SMD)
technology
50- 1000 fold higher sensitivity over existing IA
products
More than 40 Assays Available
IL-17
Singulex Single Molecule Counting (SMC)
Erenna®
4.
5.
► Elution buffer
dissociates the
complex (analyte +
detection antibody
in simple buffer)
► Transfer to 384-
well plate
► Draw eluate into the
instrument for reading
► Fluorescently labeled
antibodies introduced
to laser confocal
microscope digital
counter
► Molecules are
individually detected
and digitized
Elution Molecule counting
Proprietary Singulex technology
Sample collection
2.
3.
► Transfer samples
to 96-well plate
► Incubate with
capture magnetic
antibody-coated
beads
► Wash to remove
unbound
antibodies
► Incubate with dye-
labeled detection
antibodies
1.
► Low abundance of
certain biomarkers in
complex biological
samples
Antibody incubation Washing & fluorescent labeling
Standard immunoassay protocol
More than 40 Assays Available
Examples of Available Erenna® Assays
• IL-1b
• IL-6
• IL-17A
• IL-17F
• IL-17 A/F Heterodimer
• IFNg
• TNFa
• cTnL
• GLP-1
Parameter PBL Singulex Reported
LLOQ
(pg/ml)
0.20
0.10
0.20
Avg = 0.17
0.10
LOD
(pg/ml)
0.040
0.018
0.050
Avg = 0.04
0.03
IL-1b Assay LLOQs and LLODs
Examples of Available Cell-based IFN Assays
Cytopathic Effect (CPE) Inhibition Assay
Neutralization of 1 U of IFN in
cytopathic effect (CPE) inhibition assay
A549 human lung cancer cell line with
encephalomyocarditis virus (EMCV)
Cell-based Neutralizing Antibody Assay
Examples of Cell Proliferation & Anti-Proliferation Assays
OVCAR-3 human adenocarcinoma line TF-1 human erythroleukemia line
Proliferation quantified using soluble tetrazolium reagent
Immunoassay Products
• 10 Human Interferon ELISAs
• 3 Mouse Interferon ELISAs
• 1 Cynomolgus/Rhesus Interferon ELISA
• 1 Human soluble IFNAR2 ELISA
• 2 Multiplex ELISAs quantifying Type I, II and III IFNs
and other cytokines
• Custom Multiplex ELISAs are also possible
You can have confidence in PBL ELISAs!
• Human IFN alpha ELISA study (2008)
• Split samples run at a CRO and PBL
• Slope = 0.991
• Correlation coefficient = 0.9931
• Human IFN beta ELISA study (2009)
• Split samples run at a CRO and PBL
• Slope = 1.036
• Correlation coefficient = 0.9966
• Human IFN beta ELISA study (2014)
• P. Conliffee et al. AAPS Biotechnology Conference
• Validated analytical range 2.34 - 150 pg/ml
• Dilutional linearity up to 1 : 2187
• Interassay precision (CV) ≤13.1%
• LLOQ 2.34 pg/ml
• No IFN-b detected in normal sera.
• Median quantifiable IFN-b was 17.3 pg/ml in MS sera (n=47), with 26
quantifiable & 21 below LLOQ.
• MS samples across different sites showed excellent correlation (r2=0.9975)
VeriKine Human Interferon ELISA Kits
• Human IFNa Multisubtype Serum Kit
• Validated at numerous sites
• Kit standard calibrated to NIH human IFN alpha
standard
• Dual detection range
– 12.5 – 1000 pg/ml
• LLOD: 1.6 pg/ml; LLOQ: 5.7 pg/ml
• Intra-assay, Inter-assay, and Inter-lot CV < 8%
• Compatible with 50% normal human serum, 50%
plasma, TCM and nasal lavage
• Unique broad subtype cross reactivity
• Detects Intron-A®, Roferon®, pegylated interferon alphas
• Human Interferon Beta Serum Kit
• Developed to meet ICH guidelines on validation of
analytical procedures
• Validated at 3 independent labs to date
• Kit standard calibrated to NIH human IFN beta
standard (correlates with NIBSC standard)
• The most sensitive human IFN beta ELISA in the
market
• Detection range: 1.2 - 150 pg/ml
• LLOD: 0.3 pg/ml; LLOQ: ~2 pg/ml
• Intra-assay, Inter-assay, and Inter-lot CV < 8%
• Compatible with normal human serum, plasma,
tissue culture media
• Characterized on MS patient sera
• Detects Betaseron®, Avonex®, Cynomolgus,
Rhesus IFN beta
• Detects IFN beta bound to soluble IFNAR2
receptors
VeriKine-HS High Sensitivity
Human Interferon Beta Serum ELISA Kit
90% of Patients on IFN
Beta therapy have
quantifiable IFN Beta
2% of Healthy Donors have
1-2 pg/ml IFN-Beta
No elevation of IFN Beta
on other therapies (p=0.4)
IFN Beta in Normal and MS Patient Sera
Detected by ELISA
IFN
Beta
Treated
n=29
N
o
IFN
Treatm
entn-25
N
H
S
n=193
0
10
20
30
40
50
60
70
80
90
100
110
120
IFN-Beta(pg/ml)
New Human IFN Alpha All Subtype ELISA Kit Released in 1/2015
41105 41110 New - 41115
DMEM Normal Hu Serum Normal Hu Serum
Subtype LLOQ LLOD LLOQ LLOD LLOQ LLOD
α1 (αD) 59.21 15.07 27.75 27.75 0.63 0.18
α2a (αA) 7.13 2.00 5.72 1.62 0.57 0.16
α4a (αM1) 123.68 39.52 137.14 51.42 0.58 0.16
α5 (αG) 40.63 11.39 58.26 22.34 0.86 0.24
α6 (αK) 10.02 3.14 6.05 1.78 0.61 0.18
α7 (αJ1) 8.57 2.96 6.15 1.97 1.34 0.39
α8 (αB2) 6.84 2.95 3.54 1.08 4.97 1.60
α10 (αC) 10.03 3.60 5.98 1.79 2.69 0.90
α14 (αH) 16.18 5.73 9.73 2.61 4.13 1.36
α16 (αWA) 162.98 49.17 208.54 81.68 2.96 0.90
α17 (αI) 6.06 2.07 4.60 1.36 1.69 0.56
α21 (αF) - - - - 14.93 5.12
500-12.5 pg/mL 1000-12.5 pg/mL 125-1.95 pg/mL
New Assay sees all 12 subtypes well; more sensitive
PBL’s New Human IFNa All Subtype ELISA (Cat. 41115)
is the most sensitive assay kit on the market
Mean LLOD &
LLOQ values on
ALL 12 human
IFN-α subtypes
LLOD & LLOQ values
from IFN-α2 alone;
subtype quantitation
information available
LLOD & LLOQ values from IFN-α2 alone.
No subtype quantitation information available.
*Competitor data obtained from public sources,
provided for comparison only.
0
2
4
6
8
10
12
PBL 41115 PBL 41110 Competitor A Competitor B Competitor C Competitor D(non-
ELISA technology)
LLOD (pg/ml) LLOQ (pg/ml)
Interferon Receptor Assays
ELISA assays for soluble Type I and Type II IFN receptors
Soluble Type I and Type II Receptors are elevated in Males
sIFNAR2 ELISA Assay
sIFNAR2 Levels in Autoimmunity
Normal n=59
SLE n=111
RA n=16
Sjogren's n=11
Scleroderma n=10
0
2500
5000
7500
10000
10000
35000
p=0.008
sIFNAR2pg/ml
Reagent Products
• Proteins
– Human Interferons
– Mouse Interferons
– Rat Interferons
– Other Interferons
– Human Cytokines & Growth
Factors expressed in Human Cells
• Polyclonal Antibodies
– PAbs to Human Interferons
– PAbs to Mouse Interferons
– PAbs to Rat Interferons
– Labeled PAbs
• Monoclonal Antibodies
– MAbs to Human Interferons
– MAbs to Mouse Interferons
– MAbs to Rat Interferons
– MAbs to Porcine Interferons
– Labeled MAbs
PBL Assay Science Team
PRaDAS Quality Control
Tom Lavoie Sehrish Ajmal*
Taher Fatakdawala* Karen Zipf*
Robert Niemczyk* Production Team
Xiao-Hong Lin* Daniela Rotaru
Tara Stauffer* Karen Murphy
Michael Skawinski* Rocio Acosta
Lara Izotova* Ksenia Makarenko
Eric Zhu* Natasha Kugakolova
Barbara Schwartz
Nirupama Putcha Collaborators
Sanjna Sanghvi Ray Donnelly (FDA/NIH)
Katherine Carrino-Bednarski Phyllis Conliffe (Smithers Avanza)
Jonathan Ferreira Ira DuBey (Smithers Avanza)

More Related Content

What's hot

Disease State Plasma Newsflash - August 2014 - BBI Solutions
Disease State Plasma Newsflash - August 2014 - BBI SolutionsDisease State Plasma Newsflash - August 2014 - BBI Solutions
Disease State Plasma Newsflash - August 2014 - BBI SolutionsBBISolutions
 
Antibodies Newsflash - September 2014 - BBI Solutions
Antibodies Newsflash - September 2014 - BBI SolutionsAntibodies Newsflash - September 2014 - BBI Solutions
Antibodies Newsflash - September 2014 - BBI SolutionsBBISolutions
 
07.elisa kits for sick sinus syndrome research
07.elisa kits for sick sinus syndrome research07.elisa kits for sick sinus syndrome research
07.elisa kits for sick sinus syndrome researchElabscience
 
ELISA Kits for Edema Research
 ELISA Kits for Edema Research ELISA Kits for Edema Research
ELISA Kits for Edema ResearchElabscience
 
24 elisa kits for carcinoma of penis research
24 elisa kits for carcinoma of penis research24 elisa kits for carcinoma of penis research
24 elisa kits for carcinoma of penis researchElabscience
 
Elisa kits for upper respiratory tract infection research
Elisa kits for upper respiratory tract infection researchElisa kits for upper respiratory tract infection research
Elisa kits for upper respiratory tract infection researchElabscience
 
2018 StatLab IHC-catalog
2018 StatLab IHC-catalog2018 StatLab IHC-catalog
2018 StatLab IHC-catalogRyan Harr
 
April 2014 - Antibodies Newsflash - BBI Solutions
April 2014 - Antibodies Newsflash - BBI SolutionsApril 2014 - Antibodies Newsflash - BBI Solutions
April 2014 - Antibodies Newsflash - BBI SolutionsBBISolutions
 
Elisa kits for children urinary tract infections research
Elisa kits for children urinary tract infections researchElisa kits for children urinary tract infections research
Elisa kits for children urinary tract infections researchElabscience
 
Elisa kits for children abdominal pain research
Elisa kits for children abdominal pain researchElisa kits for children abdominal pain research
Elisa kits for children abdominal pain researchElabscience
 
09 elisa kits for hemangioma of bone research
09 elisa kits for hemangioma of bone research09 elisa kits for hemangioma of bone research
09 elisa kits for hemangioma of bone researchElabscience
 
Elisa kits for epidemic encephalitis b research
Elisa kits for epidemic encephalitis b researchElisa kits for epidemic encephalitis b research
Elisa kits for epidemic encephalitis b researchElabscience
 
09.elisa kits for rheumatic heart disease research
09.elisa kits for rheumatic heart disease research09.elisa kits for rheumatic heart disease research
09.elisa kits for rheumatic heart disease researchElabscience
 
05.elisa kits for viral encephalitis research
05.elisa kits for viral encephalitis research05.elisa kits for viral encephalitis research
05.elisa kits for viral encephalitis researchElabscience
 
Elisa kits for congenital heart disease research
Elisa kits for congenital heart disease researchElisa kits for congenital heart disease research
Elisa kits for congenital heart disease researchElabscience
 
Elisa kits for children viral myocarditis research
Elisa kits for children viral myocarditis researchElisa kits for children viral myocarditis research
Elisa kits for children viral myocarditis researchElabscience
 
Elisa kits for children acute pharyngitis research
Elisa kits for children acute pharyngitis researchElisa kits for children acute pharyngitis research
Elisa kits for children acute pharyngitis researchElabscience
 
Elisa kits for infectious mononucleosis research
Elisa kits for infectious mononucleosis researchElisa kits for infectious mononucleosis research
Elisa kits for infectious mononucleosis researchElabscience
 
01 elisa kits for malignant ascites research
01 elisa kits for malignant ascites research01 elisa kits for malignant ascites research
01 elisa kits for malignant ascites researchElabscience
 
01.elisa kits for urethral syndrome research
01.elisa kits for urethral syndrome research01.elisa kits for urethral syndrome research
01.elisa kits for urethral syndrome researchElabscience
 

What's hot (20)

Disease State Plasma Newsflash - August 2014 - BBI Solutions
Disease State Plasma Newsflash - August 2014 - BBI SolutionsDisease State Plasma Newsflash - August 2014 - BBI Solutions
Disease State Plasma Newsflash - August 2014 - BBI Solutions
 
Antibodies Newsflash - September 2014 - BBI Solutions
Antibodies Newsflash - September 2014 - BBI SolutionsAntibodies Newsflash - September 2014 - BBI Solutions
Antibodies Newsflash - September 2014 - BBI Solutions
 
07.elisa kits for sick sinus syndrome research
07.elisa kits for sick sinus syndrome research07.elisa kits for sick sinus syndrome research
07.elisa kits for sick sinus syndrome research
 
ELISA Kits for Edema Research
 ELISA Kits for Edema Research ELISA Kits for Edema Research
ELISA Kits for Edema Research
 
24 elisa kits for carcinoma of penis research
24 elisa kits for carcinoma of penis research24 elisa kits for carcinoma of penis research
24 elisa kits for carcinoma of penis research
 
Elisa kits for upper respiratory tract infection research
Elisa kits for upper respiratory tract infection researchElisa kits for upper respiratory tract infection research
Elisa kits for upper respiratory tract infection research
 
2018 StatLab IHC-catalog
2018 StatLab IHC-catalog2018 StatLab IHC-catalog
2018 StatLab IHC-catalog
 
April 2014 - Antibodies Newsflash - BBI Solutions
April 2014 - Antibodies Newsflash - BBI SolutionsApril 2014 - Antibodies Newsflash - BBI Solutions
April 2014 - Antibodies Newsflash - BBI Solutions
 
Elisa kits for children urinary tract infections research
Elisa kits for children urinary tract infections researchElisa kits for children urinary tract infections research
Elisa kits for children urinary tract infections research
 
Elisa kits for children abdominal pain research
Elisa kits for children abdominal pain researchElisa kits for children abdominal pain research
Elisa kits for children abdominal pain research
 
09 elisa kits for hemangioma of bone research
09 elisa kits for hemangioma of bone research09 elisa kits for hemangioma of bone research
09 elisa kits for hemangioma of bone research
 
Elisa kits for epidemic encephalitis b research
Elisa kits for epidemic encephalitis b researchElisa kits for epidemic encephalitis b research
Elisa kits for epidemic encephalitis b research
 
09.elisa kits for rheumatic heart disease research
09.elisa kits for rheumatic heart disease research09.elisa kits for rheumatic heart disease research
09.elisa kits for rheumatic heart disease research
 
05.elisa kits for viral encephalitis research
05.elisa kits for viral encephalitis research05.elisa kits for viral encephalitis research
05.elisa kits for viral encephalitis research
 
Elisa kits for congenital heart disease research
Elisa kits for congenital heart disease researchElisa kits for congenital heart disease research
Elisa kits for congenital heart disease research
 
Elisa kits for children viral myocarditis research
Elisa kits for children viral myocarditis researchElisa kits for children viral myocarditis research
Elisa kits for children viral myocarditis research
 
Elisa kits for children acute pharyngitis research
Elisa kits for children acute pharyngitis researchElisa kits for children acute pharyngitis research
Elisa kits for children acute pharyngitis research
 
Elisa kits for infectious mononucleosis research
Elisa kits for infectious mononucleosis researchElisa kits for infectious mononucleosis research
Elisa kits for infectious mononucleosis research
 
01 elisa kits for malignant ascites research
01 elisa kits for malignant ascites research01 elisa kits for malignant ascites research
01 elisa kits for malignant ascites research
 
01.elisa kits for urethral syndrome research
01.elisa kits for urethral syndrome research01.elisa kits for urethral syndrome research
01.elisa kits for urethral syndrome research
 

Similar to 2015 PBL Assay Solutions

MDC Connects: Biomarker identification - Assessing Immune Function
MDC Connects: Biomarker identification - Assessing Immune FunctionMDC Connects: Biomarker identification - Assessing Immune Function
MDC Connects: Biomarker identification - Assessing Immune FunctionMedicines Discovery Catapult
 
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellAAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellLawrence Hwang
 
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...QIAGEN
 
Nanodevices for the detection of disease by Maurits de Planque
Nanodevices for the detection of disease by  Maurits de PlanqueNanodevices for the detection of disease by  Maurits de Planque
Nanodevices for the detection of disease by Maurits de Planqueonthewight
 
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassaysMichael A. Lomotan
 
2017 molecular profiling_wim_vancriekinge
2017 molecular profiling_wim_vancriekinge2017 molecular profiling_wim_vancriekinge
2017 molecular profiling_wim_vancriekingeProf. Wim Van Criekinge
 
Enabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsEnabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsDiscoverX Corporation
 
A rapid library preparation method with custom assay designs for detection of...
A rapid library preparation method with custom assay designs for detection of...A rapid library preparation method with custom assay designs for detection of...
A rapid library preparation method with custom assay designs for detection of...Thermo Fisher Scientific
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesSean Ekins
 
Transfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendationsTransfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendationssanjay negi
 

Similar to 2015 PBL Assay Solutions (20)

Elis arrays
Elis arraysElis arrays
Elis arrays
 
Biopra activities
Biopra activitiesBiopra activities
Biopra activities
 
MDC Connects: Biomarker identification - Assessing Immune Function
MDC Connects: Biomarker identification - Assessing Immune FunctionMDC Connects: Biomarker identification - Assessing Immune Function
MDC Connects: Biomarker identification - Assessing Immune Function
 
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_RussellAAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_Russell
 
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...
 
Presentation 6
Presentation 6Presentation 6
Presentation 6
 
Nanodevices for the detection of disease by Maurits de Planque
Nanodevices for the detection of disease by  Maurits de PlanqueNanodevices for the detection of disease by  Maurits de Planque
Nanodevices for the detection of disease by Maurits de Planque
 
Cignal webina
Cignal webinaCignal webina
Cignal webina
 
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
44-150724PST_Peptalk_2013_AlphaLISA_immunoassays
 
2017 molecular profiling_wim_vancriekinge
2017 molecular profiling_wim_vancriekinge2017 molecular profiling_wim_vancriekinge
2017 molecular profiling_wim_vancriekinge
 
Yuva CRO services
Yuva CRO servicesYuva CRO services
Yuva CRO services
 
Enabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsEnabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to Combinations
 
Toxikon by kevin breesch
Toxikon by kevin breeschToxikon by kevin breesch
Toxikon by kevin breesch
 
Nat Testing
Nat TestingNat Testing
Nat Testing
 
Axt microarrays
Axt microarraysAxt microarrays
Axt microarrays
 
A rapid library preparation method with custom assay designs for detection of...
A rapid library preparation method with custom assay designs for detection of...A rapid library preparation method with custom assay designs for detection of...
A rapid library preparation method with custom assay designs for detection of...
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
 
ELISA..pptx
ELISA..pptxELISA..pptx
ELISA..pptx
 
Testing for Food Authenticity
Testing for Food AuthenticityTesting for Food Authenticity
Testing for Food Authenticity
 
Transfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendationsTransfusion tranmitted Infection- Testing platform& recommendations
Transfusion tranmitted Infection- Testing platform& recommendations
 

2015 PBL Assay Solutions

  • 1. “For over 24 years, we’ve worked hand in hand with industry, academic, and government researchers to help solve difficult assay development and protein quantification problems.” Stephen Parent, PhD Director of Business Development sparent@pblbio.com (732) 777-9123 x117
  • 2. PBL Assay Science History • Founded in 1990 by Dr. Sidney Pestka • 35 employees based in Piscataway, NJ • World’s largest producer of interferons and related cytokine products for the research market – ELISA and multiplex assay kits – Recombinant proteins – Antibodies – Assay services – Custom services
  • 3. High Quality Assay Solutions Interrogating Interferon and Cytokine Biology
  • 4. Assay Solutions Interrogating IFN and Cytokine Biology • Off the Shelf Assays – More than 70 Interferon ELISAs, antibodies and cell- based assays • Assay Services Offerings – Sample Testing and Screening – More than 40 Singulex Erenna biomarker assays – Assay Design and Development – Custom Services – We provide ~ 70 different services
  • 5. Assay Services Capabilities Cell-Based Assay Development Antiviral Assays Cytokine/Chemokine Bioactivity Assays Immunoassays Development Single Analyte & Multiplex ELISAs Ultrasensitive Cytokine Detection Assays using Singulex Erenna® technology More than 40 Assays Available Human and Mouse Reagent Development & Characterization Assay Optimization Technology Transfer Consulting in Assay Development and Therapeutics Development
  • 6. IL-17 Ultrasensitive Cytokine Detection Service using Singulex Erenna® Immunoassay System Modified IA process using magnetic beads Single Molecule Detection (SMD) technology 50- 1000 fold higher sensitivity over existing IA products More than 40 Assays Available
  • 7. IL-17 Singulex Single Molecule Counting (SMC) Erenna® 4. 5. ► Elution buffer dissociates the complex (analyte + detection antibody in simple buffer) ► Transfer to 384- well plate ► Draw eluate into the instrument for reading ► Fluorescently labeled antibodies introduced to laser confocal microscope digital counter ► Molecules are individually detected and digitized Elution Molecule counting Proprietary Singulex technology Sample collection 2. 3. ► Transfer samples to 96-well plate ► Incubate with capture magnetic antibody-coated beads ► Wash to remove unbound antibodies ► Incubate with dye- labeled detection antibodies 1. ► Low abundance of certain biomarkers in complex biological samples Antibody incubation Washing & fluorescent labeling Standard immunoassay protocol More than 40 Assays Available
  • 8. Examples of Available Erenna® Assays • IL-1b • IL-6 • IL-17A • IL-17F • IL-17 A/F Heterodimer • IFNg • TNFa • cTnL • GLP-1 Parameter PBL Singulex Reported LLOQ (pg/ml) 0.20 0.10 0.20 Avg = 0.17 0.10 LOD (pg/ml) 0.040 0.018 0.050 Avg = 0.04 0.03 IL-1b Assay LLOQs and LLODs
  • 9. Examples of Available Cell-based IFN Assays Cytopathic Effect (CPE) Inhibition Assay Neutralization of 1 U of IFN in cytopathic effect (CPE) inhibition assay A549 human lung cancer cell line with encephalomyocarditis virus (EMCV) Cell-based Neutralizing Antibody Assay
  • 10. Examples of Cell Proliferation & Anti-Proliferation Assays OVCAR-3 human adenocarcinoma line TF-1 human erythroleukemia line Proliferation quantified using soluble tetrazolium reagent
  • 11. Immunoassay Products • 10 Human Interferon ELISAs • 3 Mouse Interferon ELISAs • 1 Cynomolgus/Rhesus Interferon ELISA • 1 Human soluble IFNAR2 ELISA • 2 Multiplex ELISAs quantifying Type I, II and III IFNs and other cytokines • Custom Multiplex ELISAs are also possible
  • 12. You can have confidence in PBL ELISAs! • Human IFN alpha ELISA study (2008) • Split samples run at a CRO and PBL • Slope = 0.991 • Correlation coefficient = 0.9931 • Human IFN beta ELISA study (2009) • Split samples run at a CRO and PBL • Slope = 1.036 • Correlation coefficient = 0.9966 • Human IFN beta ELISA study (2014) • P. Conliffee et al. AAPS Biotechnology Conference • Validated analytical range 2.34 - 150 pg/ml • Dilutional linearity up to 1 : 2187 • Interassay precision (CV) ≤13.1% • LLOQ 2.34 pg/ml • No IFN-b detected in normal sera. • Median quantifiable IFN-b was 17.3 pg/ml in MS sera (n=47), with 26 quantifiable & 21 below LLOQ. • MS samples across different sites showed excellent correlation (r2=0.9975)
  • 13. VeriKine Human Interferon ELISA Kits • Human IFNa Multisubtype Serum Kit • Validated at numerous sites • Kit standard calibrated to NIH human IFN alpha standard • Dual detection range – 12.5 – 1000 pg/ml • LLOD: 1.6 pg/ml; LLOQ: 5.7 pg/ml • Intra-assay, Inter-assay, and Inter-lot CV < 8% • Compatible with 50% normal human serum, 50% plasma, TCM and nasal lavage • Unique broad subtype cross reactivity • Detects Intron-A®, Roferon®, pegylated interferon alphas • Human Interferon Beta Serum Kit • Developed to meet ICH guidelines on validation of analytical procedures • Validated at 3 independent labs to date • Kit standard calibrated to NIH human IFN beta standard (correlates with NIBSC standard) • The most sensitive human IFN beta ELISA in the market • Detection range: 1.2 - 150 pg/ml • LLOD: 0.3 pg/ml; LLOQ: ~2 pg/ml • Intra-assay, Inter-assay, and Inter-lot CV < 8% • Compatible with normal human serum, plasma, tissue culture media • Characterized on MS patient sera • Detects Betaseron®, Avonex®, Cynomolgus, Rhesus IFN beta • Detects IFN beta bound to soluble IFNAR2 receptors
  • 14. VeriKine-HS High Sensitivity Human Interferon Beta Serum ELISA Kit 90% of Patients on IFN Beta therapy have quantifiable IFN Beta 2% of Healthy Donors have 1-2 pg/ml IFN-Beta No elevation of IFN Beta on other therapies (p=0.4) IFN Beta in Normal and MS Patient Sera Detected by ELISA IFN Beta Treated n=29 N o IFN Treatm entn-25 N H S n=193 0 10 20 30 40 50 60 70 80 90 100 110 120 IFN-Beta(pg/ml)
  • 15. New Human IFN Alpha All Subtype ELISA Kit Released in 1/2015 41105 41110 New - 41115 DMEM Normal Hu Serum Normal Hu Serum Subtype LLOQ LLOD LLOQ LLOD LLOQ LLOD α1 (αD) 59.21 15.07 27.75 27.75 0.63 0.18 α2a (αA) 7.13 2.00 5.72 1.62 0.57 0.16 α4a (αM1) 123.68 39.52 137.14 51.42 0.58 0.16 α5 (αG) 40.63 11.39 58.26 22.34 0.86 0.24 α6 (αK) 10.02 3.14 6.05 1.78 0.61 0.18 α7 (αJ1) 8.57 2.96 6.15 1.97 1.34 0.39 α8 (αB2) 6.84 2.95 3.54 1.08 4.97 1.60 α10 (αC) 10.03 3.60 5.98 1.79 2.69 0.90 α14 (αH) 16.18 5.73 9.73 2.61 4.13 1.36 α16 (αWA) 162.98 49.17 208.54 81.68 2.96 0.90 α17 (αI) 6.06 2.07 4.60 1.36 1.69 0.56 α21 (αF) - - - - 14.93 5.12 500-12.5 pg/mL 1000-12.5 pg/mL 125-1.95 pg/mL New Assay sees all 12 subtypes well; more sensitive
  • 16. PBL’s New Human IFNa All Subtype ELISA (Cat. 41115) is the most sensitive assay kit on the market Mean LLOD & LLOQ values on ALL 12 human IFN-α subtypes LLOD & LLOQ values from IFN-α2 alone; subtype quantitation information available LLOD & LLOQ values from IFN-α2 alone. No subtype quantitation information available. *Competitor data obtained from public sources, provided for comparison only. 0 2 4 6 8 10 12 PBL 41115 PBL 41110 Competitor A Competitor B Competitor C Competitor D(non- ELISA technology) LLOD (pg/ml) LLOQ (pg/ml)
  • 18. ELISA assays for soluble Type I and Type II IFN receptors Soluble Type I and Type II Receptors are elevated in Males
  • 19. sIFNAR2 ELISA Assay sIFNAR2 Levels in Autoimmunity Normal n=59 SLE n=111 RA n=16 Sjogren's n=11 Scleroderma n=10 0 2500 5000 7500 10000 10000 35000 p=0.008 sIFNAR2pg/ml
  • 20. Reagent Products • Proteins – Human Interferons – Mouse Interferons – Rat Interferons – Other Interferons – Human Cytokines & Growth Factors expressed in Human Cells • Polyclonal Antibodies – PAbs to Human Interferons – PAbs to Mouse Interferons – PAbs to Rat Interferons – Labeled PAbs • Monoclonal Antibodies – MAbs to Human Interferons – MAbs to Mouse Interferons – MAbs to Rat Interferons – MAbs to Porcine Interferons – Labeled MAbs
  • 21. PBL Assay Science Team PRaDAS Quality Control Tom Lavoie Sehrish Ajmal* Taher Fatakdawala* Karen Zipf* Robert Niemczyk* Production Team Xiao-Hong Lin* Daniela Rotaru Tara Stauffer* Karen Murphy Michael Skawinski* Rocio Acosta Lara Izotova* Ksenia Makarenko Eric Zhu* Natasha Kugakolova Barbara Schwartz Nirupama Putcha Collaborators Sanjna Sanghvi Ray Donnelly (FDA/NIH) Katherine Carrino-Bednarski Phyllis Conliffe (Smithers Avanza) Jonathan Ferreira Ira DuBey (Smithers Avanza)